CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing

Negative
AI Analysis

Summary

Cellectis, a French biotech previously focused on donor-derived CAR-T cell therapy, is exiting the CAR-T space and pivoting toward in vivo gene editing programs. The company is divesting its lead CAR-T programs in response to changing market conditions.

Importance:5/10
Sentiment:
-0.60
strategy_shiftCAR-Tgene_editingpipeline_changedivestment
Related Companies

Read the original article

Published by BioPharma Dive on September 14, 2026 3:46 PM

Read Original